Ongoing conflict in the Middle East region has left thousands of families displaced in Lebanon, with an increase in food poverty, poor water sanitation and illness observed. MANCH ...
New consumer research reveals women and people with cycles spend an average of £20,359 on menstruating in their lifetime ; More than 1 in 3 (37%) of respondents struggle to affor ...
As medical students across the country learn where they will train during Match Day, ApolloMD is opening applications for its 2026 Emergency Medicine Scholarship. The annual award now provides $5,000 ...
Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical ...
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer ; The lead ...
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...
The Company reported total revenues of $6,715,175 for the year ended December 31, 2025 ("fiscal year 2025”), compared to $6,065,390 for the year ended December 31, 2024 ("fiscal year 2024”). The ...
First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or ...
Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2025 operating and financial results and reviewed recent business highlights. “Over the past year ...
This Women's History Month, Lume Deodorant founder and lobular breast cancer survivor, Dr. Shannon Klingman, has made a historic $1 million gift to the Lobular Breast Cancer Alliance (LBCA) to fund ...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET.
We finished 2025 with double-digit overall revenue growth in the fourth quarter with continued growth in our Canadian pharmaceutical business and sizable contributions from our international Tibelia ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results